Inovio Completes Enrollment Ahead of Schedule In Immuno-Oncolo...
PLYMOUTH MEETING, Pa., April 1, 2019 /PRNewswire-AsiaNet/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM) has completed its enrollment three months ahead of schedule. The 52-patient trial is designed t...
Authors: LATEST ASIANET NEWS RELEASES